Industry: Psychedelics

Funding for psychedelic startups

Investors in psychedelic medicine now pay for late-stage data, FDA filings and the clinics that will give each dose. We build that case for drug developers and therapy clinics.

  • Investor materials for drug developers and therapy clinics
  • Models built on trial costs, rescheduling and clinic capacity
  • Waveup prepares investor materials for psychedelic medicine companies: $3B+ raised for 600+ startups since 2014

In short

What is funding for psychedelic startups?

Funding for psychedelic startups is the money raised by psilocybin, LSD and MDMA drug developers and by psychedelic therapy clinics. It comes from neuroscience funds, life sciences investors, public markets and drugmakers that license or buy drugs. In Q2 2026 the field raised just over $1B, a record, but one company took most of it.

Who it's for
Psychedelic drug developers and therapy clinics, pre-seed to Series D+
What we build
Investor deck, financial model, valuation, investor list, data room
Track record
$3B+ raised for 600+ startups since 2014

Market data checked on 6 November 2026. Sources are under each section.

Are investors back in psychedelic medicine in 2026?

Yes, for drug developers with late-stage data. Early-stage companies and clinics still find money scarce.

The opportunity

The first psychedelic drugs are nearing FDA decisions, and big drugmakers have started buying.

  • Compass Pathways expects to finish its psilocybin drug application in November 2026
  • AbbVie and Otsuka have each bought a drug programme in the field
  • An April 2026 executive order backs faster FDA reviews for breakthrough-designated psychedelics

The problem

Most of the money goes to a few listed drug developers with Phase 3 data. In Q2 2026, Definium alone raised $805M, while very few private companies raised at all.

Market size

How big is the market for psychedelic medicine, and what will drive it?

No psilocybin, LSD or MDMA medicine is approved in the US yet, so there are no sales to count. The nearest guide is J&J's Spravato, a ketamine-based nasal spray taken in certified clinics. It sold $1.7 billion worldwide in 2025. Four things will shape demand for the first approved psychedelic drugs:

  • Late-stage data: Definium's LSD drug, DT120, reported positive results in three Phase 3 trials in 2026
  • Faster reviews: a national priority voucher could cut Compass's FDA review to 1–2 months
  • Federal money: a 2026 executive order directs at least $50M to state psychedelic programmes
  • Supervised services: Oregon's licensed psilocybin service centers served 5,935 clients in 2025
Psilocybin studies on ClinicalTrials.gov by start year: 1 in 2016, 24 in 2021 and 53 in 2025.

Psychedelic medicine in 2026, in six numbers

$1.225B

Otsuka's total potential price for Transcend Therapeutics, a PTSD drug developer (March 2026)

$1.2B

AbbVie's maximum price for bretisilocin, Gilgamesh's psychedelic drug for depression (August 2025)

20%

minimum share of IP revenue Texas keeps from the ibogaine trials it funds, under a 2025 law

$748,926

psilocybin product sales in Oregon's licensed program in all of 2025

310

studies on ClinicalTrials.gov that list psilocybin as an intervention, as of 6 November 2026

$444M

cash Compass Pathways held on 30 September 2026, as its FDA filing neared completion

Venture capital

How much money reaches psychedelic companies now?

Psychedelic financing rises and falls with trial results. Q2 2026 set a record after Definium's Phase 3 data, but few private companies raised that quarter.

Psychedelic financing: just over $16M in Q4 2023, about $37.5M in Q3 2024, $348M in Q1 2026 and $1B+ in Q2 2026.
10

financings in Q2 2026, which brought in just over $1B, a quarterly record

$133M

Series A total for Reunion Neuroscience after its 2025 extension

$60M

Series A for Gilgamesh Pharma in early 2026, after AbbVie bought its parent's lead drug

Who invests in psychedelic startups?

Neuroscience and psychedelics funds, a life sciences VC and drugmakers that buy programmes. For more names, see our list of psychedelic venture capital firms.

Investor
Type and base
Psychedelic companies backed
Stage or cheque
PsyMed Ventures
Neuroscience VC, Berkeley (California)
Beckley Psytech, Tactogen, Journey Clinical
Not stated
Palo Santo
Neuroscience fund; base not stated on its site
Reunion Neuroscience, Transcend Therapeutics, Delix Therapeutics
Not stated
Satori Neuro (Satori Capital)
Brain and mental health investor, Dallas
Gilgamesh, Sunstone Therapies
Not stated
MPM BioImpact
Life sciences VC, Boston
Reunion Neuroscience; most of its portfolio, such as Dyne Therapeutics, is outside psychedelics
Seed to follow-on rounds
Otsuka Pharmaceutical
Drugmaker and buyer, Japan
Mindset Pharma and Transcend Therapeutics, both acquired
Acquisitions; up to $1.225B for Transcend
AbbVie
Drugmaker, North Chicago (Illinois)
Gilgamesh Pharmaceuticals, whose drug bretisilocin it agreed to buy in 2025
Up to $1.2B for one drug

Investor database

Pharma investors in our database

The funds with the most pharma investments. Pick a stage, or open a fund for its cheque sizes.

Top 5 by pharma investments

  • Investments by industry

    • Healthtech & Wellness42%
    • Pharma19%
    • Biotech17%
    Rounds
    Pre-seedSeed
    Average cheque
    Not listed
    Based in
    Los Angeles, California, United States

    28 investments in total, 7 tagged Pharma.Open the full fund profile

  • Investments by industry

    • Healthtech & Wellness40%
    • Software & Apps15%
    • Pharma7%
    Rounds
    Pre-seedSeedSeries ASeries BSeries C+
    Average cheque
    Not listed
    Based in
    Dallas, United States
    Invests in
    USA

    88 investments in total, 7 tagged Pharma.Open the full fund profile

  • Investments by industry

    • Healthtech & Wellness49%
    • Biotech20%
    • Pharma14%
    Rounds
    SeedSeries A
    Average cheque
    Not listed
    Based in
    Toronto, Ontario, Canada

    25 investments in total, 5 tagged Pharma.Open the full fund profile

  • Investments by industry

    • Biotech21%
    • Healthtech & Wellness19%
    • Hardware. Robotics & IoT17%
    • Pharma7%
    Rounds
    SeedSeries ASeries BSeries C+
    Average cheque
    $1M–$3M$3M–$10M
    Based in
    Jackson, United States
    Invests in
    USA

    62 investments in total, 3 tagged Pharma.Open the full fund profile

  • Investments by industry

    • Healthtech & Wellness50%
    • Biotech19%
    • Pharma6%
    Rounds
    Seed
    Average cheque
    Not listed
    Based in
    San Francisco, United States
    Invests in
    Europe, USA, Canada

    33 investments in total, 2 tagged Pharma.Open the full fund profile

From our investor database.

Why do investors hesitate on psychedelic companies?

In our Fundraising 2025 study, 56 VCs named burn and missed milestones among their top reasons to say no. Psychedelic developers face long trials and a second approval step, so both risks weigh heavily.

Costly dosing sessions

FDA guidance from July 2026 expects two trained monitors in the room for each full dosing session. Every trial visit carries those staff hours.

What investors ask

  • What does one dosing session cost, and how many does your trial need?

What your deck shows

  • Cost per session, with staff hours
  • Trial budget and cash to each readout

Approval isn't launch

Many psychedelics are Schedule I drugs, so an approved product also needs DEA and state rescheduling. Compass says about 90% of US patients live in states that intend to reschedule within weeks.

What investors ask

  • How long from FDA approval to first sale, state by state?

What your deck shows

  • A timeline from filing to DEA and state rescheduling
  • A launch plan that starts where rules allow

Clinic hours cap sales

Spravato patients must stay in a certified clinic for at least two hours after each dose. The FDA notes that patients may stay vulnerable for several hours or longer after a psychedelic dose.

What investors ask

  • How many sessions can one room run a day, and who pays for that time?

What your deck shows

  • Revenue and staff cost per session and per room
  • A payer plan, or a cash price clinics will accept

A gap after early data

Psychedelic Alpha found no announced private Series B or C rounds from 2023 until mid-2025. Even in Q2 2026's record quarter, very few private companies raised.

What investors ask

  • How will you fund the step from early data to Phase 3?

What your deck shows

  • The milestone each tranche of money reaches
  • Licensing, partnering or grant options beside equity

How we help you raise

Flat fees agreed before we start. No success fee on advisory work.

    From $6,000

    Trial data, the FDA and DEA path and your clinic model in one story.

    From $3,000

    Trial costs, session staffing, launch timing and runway, month by month.

    From $5,000

    A range built on recent psychedelic deals and the risk left before approval.

    Neuroscience funds, life sciences VCs, drugmakers and grant bodies for your stage.

    Trial records, DEA registrations, patents and contracts, ready for review.

    For a licensing deal, an asset sale or a buyer's diligence.

Who we are

Waveup is a London-based fundraising and growth advisory, working in 60+ countries and 90+ industries. Since 2014 we have built the decks, models, CIMs and valuations behind $3B+ raised for 600+ startups. Biotech and pharma are the largest group among our 54+ deep-tech projects.

About us
Track record
$3B+
raised for 600+ startups
Decks
1,000+
decks since 2014
M&A
50+
M&A transactions supported, including 20+ exits
Health
11%
of our projects on record are in healthcare and life sciences

Funding for psychedelic startups FAQ

How do psychedelic startups get funding?
Most start with founders, angels and neuroscience funds such as PsyMed Ventures or Palo Santo. Grants and state programmes can pay for early trials. Some come with strings: Texas keeps at least 20% of IP revenue from the ibogaine trials it funds. Larger rounds usually follow human data, from life sciences investors or public markets. Drugmakers then license or buy programmes. Our guide to non-dilutive funding compares grants and loans.
Which companies are developing psychedelic medicines?
Are psychedelics becoming legal in the US?
What do investors look for in a psychedelic drug developer?
Can a psychedelic therapy clinic raise venture capital?
How much does help with a psychedelic company's raise cost?

Raising for a psychedelic medicine company?

Tell us your drug or clinic model and the round you plan. We'll flag what investors will question first.

Have a project in mind?

Leave your information below and one of our experts will be in touch to schedule a call.

Your name:
*Your email:
*You need help with:
Your project is:
Your current stage:
Your maximum budget:
How did you find us?